Oligometastatic disease, a new concept: Stereotactic irradiation for lung metastases. Literature review;Maladie oligométastatique, un nouveau concept : Irradiation en conditions stéréotaxiques de métastases pulmonaires. Revue de la littérature

Cancer/Radiotherapie

Volumn 16, Issue 5-6, 2012, Pages 351-357

  Hatime, M ^a   Elmorabit, B ^a   Elkhoti, Y ^a   Touch, S ^a   Tanguy, R ^a   Mornex, F ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Irradiation tolerance; Lung cancer; Oligometastases; Radiotherapy; SBRT; Stereotactic irradiation; Therapeutic innovation

Indexed keywords

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; LUNG METASTASIS; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; SHORT SURVEY; STEREOTACTIC BODY RADIATION THERAPY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG; LUNG NEOPLASMS; PATIENT SELECTION; RADIOSURGERY; RADIOTHERAPY DOSAGE;

EID: 84866430845     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2012.07.184     Document Type: Short Survey

References (54)

1. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995, 13:8-10.
2. Nagata Y., Negoro Y., Aoki T., Mizowaki T., Takayama K., Kokubo M., et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002, 52:1041-1046.
3. Norihisa Y., Nagata Y., Takayama K., Matsuo Y., Sakamoto T., Sakamoto M., et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008, 72:398-403.
4. Lee S.W., Choi E.K., Park H.J., Ahn S.D., Kim J.H., Kim K.J., et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003, 40:309-315.
5. Wulf J., Haedinger U., Oppitz U., Thiele W., Mueller G., Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004, 60:186-196.
6. Zimmermann F.B., Geinitz H., Schill S., Grosu A., Schratzenstaller U., Molls M., et al. Stereotactic hypo-fractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005, 48:107-114.
7. Niibe Y., Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010, 40:107-111.
8. Baumann P., Nyman J., Hoyer M., Wennberg B., Gagliardi G., Lax I., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer in patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
9. Schefter T.E., kavanagh B.D., Raben D. A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: initial report of dose escalation and early toxicity. Int J Radiat Oncol Biol Phys 2006, 66:120-127.
10. Milano M.T., Philip A., Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 2009, 73:832-837.
11. Siva S., MacManus M., Ball D. Stereotactic radiotherapy for pulmonary oligometastases. A systematic review. J Thorac Oncol 2010, 5:1091-1099.
12. Ricardi U., Filippi A.R., Guarneri A., Ragona R., Mantovani C., Giglioli F., et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012, 75:77-81.
13. Guckenberger M., Heilman K., Wulf J., Mueller G., Beckmann G., Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol 2007, 85:435-442.
14. Nagata Y., Takayama K., Matsuo Y., Norihisa Y., Mizowaki T., Sakamoto T., et al. Clinical outcomes of a phase I/II study of 48Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427-1431.
15. Girard N., Mornex F. Radiothérapie stéréotaxique des cancers broncho-pulmonaires non à petites cellules : d'un concept à une réalité clinique. Actualités en 2011. Cancer Radiother 2011, 15:522-526.
16. Fritz P., Kraus H.J., Mühlnickel W., Hammer U., Dölken W., Engel-Riedel W., et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 2006, 1:30.
17. Rusthoven K.E., Kavanagh B.D., Burri S.H., Chen C., Cardenes H., Chidel M.A., et al. Multi-institutional phase I/II Trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584.
18. Haasbeek C.J., Lagerwaard F.J., Slotman B., Senan S. Late outcomes of stereotactic ablative radiotherapy (SABR) for centrally located stage I lung cancer. J Thorac Oncol 2011, 6:S542.
19. Palma D., Lagerwaard F.J., Rodrigues G., Haasbeek C.J., Senan S. Curative treatment of stage I non-small cell Lung cancer in patients with severe COPD: stereo-tactic radiotherapy outcomes and systematic review. J Thorac Oncol 2011, 6:S384.
20. Lagerwaard F.J., Verstegen N.E., Haasbeek C.J., Slotman B., Paul M.A., Smit E.F., et al. Stereotactic ablative radiotherapy (SABR) in potentially operable stage I non-small cell lung cancer patients. J Thorac Oncol 2011, 6:S278.
21. Okunieff P., Petersen A.L., Philip A., Milano M.T., Katz A.W., Boros L., et al. Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol 2006, 45:808-817.
22. Ernst-Stecken A., Lambrecht U., Mueller R., Sauer R., Grabenbauer G. Hypofractionated stereotactic radiotherapy for primary and secondary intrapulmonary tumors. Strahlenther Onkol 2006, 182:696-702.
23. Kimura T., Matsuura K., Murakami Y., Hashimoto Y., Kenjo M., Kaneyasu Y., et al. CT appearance of radiation injury of the lung and clinical symptoms after stereo-tactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?. Int J Radiat Oncol Biol Phys 2006, 66:483-491.
24. Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
25. Takeda A., Kunieda E., Takeda T., Tanaka M., Sanuki N., Fujii H., et al. Possible misinterpretation of demarcated solid patterns of radiation fibrosis on CT scans as tumor recurrence in patients receiving hypofractionated stereotactic radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys 2008, 70:1057-1065.
26. Xia T., Li H., Sun Q., Wang Y., Fan N., Yu Y., et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:117-125.
27. Onimaru R., Fujino M., Yamazaki K., Onodera Y., Taguchi H., Katoh N., et al. Steep dose response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:374-381.
28. Yamashita H., Nakagawa K., Nakamura N., Koyanagi H., Tago M., Igaki H., et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2007, 2:21.
29. Blomgren H., Lax I., Goranson H. Radiosurgery for tumors in the body. Clinical experience using a new method. J Radiosurg 1998, 1:63-74.
30. Song D.Y., Benedict S.H., Cardinale R.M., Chung T.D., Chang M.G., Schmidt-Ullrich R.K. Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits. Am J Clin Oncol 2005, 28:591-596.
31. Wul F.J., Hadinger U., Oppitz U., Thiele W., Ness-Dourdoumas R., Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001, 177:645-655.
32. Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
33. Uematsu M., Fukui T., Tahara K., Sato N., Shiota A., Wong J. Long-term results of computed tomography guided hypofractionated stereotactic radiotherapy for stage I non-small cell lung cancers [abstract]. Int J Radiat Oncol Biol Phys 2008, 72:S36.
34. Joyner M., Salter B.J., Papanikolaou N., Fuss M. Stereotactic body radiation therapy for centrally located lung lesions. Acta Oncol 2006, 45:802-807.
35. Zimmermann F.B., Geinitz H., Schill S., Thamm R., Nieder C., Schratzenstaller U., et al. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 2006, 45:796-801.
36. Chang J.Y., Balter P., Dong L., Bucci M.K., Liao Z., Jeter M.D., et al. Early results of stereotactic body radiation therapy (SBRT) in centrally/superiorly located stage I or isolated recurrent NSCLC [abstract]. Int J Radiat Oncol Biol Phys 2008, 72:S463.
37. Forquer J.A., Fakiris A.J., Timmerman R.D., Lo S.S., Perkins S.M., McGarry R.C., et al. Brachial plexopathy (BP) from stereotactic body radiotherapy (SBRT) in early-stage NSCLC: dose limiting toxicity in apical tumor sites [abstract]. Int J Radiat Oncol Biol Phys 2008, 72:S36-S37.
38. De Ruysscher D., Faivre-Finn C., Nestle U., Hurkmans C.W., Le Péchoux C., Price A., et al. European organisation for research and treatment of cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010, 28:5301-5310.
39. Rosenzweig K. Normal tissue constraints for SBRT. J Thoracic Oncol 2011, 6:S85. [abstract].
40. Timmerman R., Papiez L., McGarry R., Likes L., DesRosiers C., Frost S., et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124:1946.
41. Brown W.T., Wu X., Fayad F., Fowler J.F., Amendola B.E., Garcia S., et al. CyberKnife radiosurgery for stage I lung cancer: results at 36months. Clin Lung Cancer 2007, 8:488.
42. Le Q.T., Loo B.W., Ho A., Cotrutz C., Koong A.C., Wakelee H., et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006, 1:802-809.
43. McGarry R.C., Papiez L., Williams M., Whitford T., Timmerman R.D. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005, 63:1010-1015.
44. Haasbeek C.J., Lagerwaard F.J., Antonisse M.E., Slotman B.J., Senan S. Stage I non-small cell lung cancer in patients aged 75years: outcomes after stereotactic radiotherapy. Cancer 2010, 116:406.
45. Onishi H., Araki T., Shirato H., Nagata Y., Hiraoka M., Gomi K., et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multi-institutional study. Cancer 2004, 101:1623-1631.
46. Wulf J., Baier K., Mueller G., et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005, 77:83-87.
47. Pastorino U., Buyse M., Friedel G., Ginsberg R., Girard P., Goldstraw P., et al. Long-term results of lung metastasectomy: prognositic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997, 113:37-49.
48. Kavanagh B.D., McGarry R.C., Timmerman R.D. Extracranial radiosurgery (Stereotactic Body Radiation Therapy) for oligometastases. Semin Radiat Oncol 2006, 16:77-84.
49. Yin F.F., Das S., Kirkpatrick J., Oldham M., Wang Z., Zhou S.M. Physics and imaging for targeting of oligometastases. Semin Radiat Oncol 2006, 16:85-101.
50. Henderson M.A., Hoopes D.J., Fletcher J.W., Lin P.F., Tann M., Yiannoutsos C.T., et al. A pilot trial of serial 18f-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:789-795.
51. Vera P., Bohn P., Edet-Sanson A., Salles A., Hapdey S., Gardin I., et al. Simultaneous positron emission tomography (PET) assessment of metabolism with 18F-fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine (FLT), and hypoxia with 18fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 2011, 98:109-116.
52. Lagerwaard F.J., Aaronson N.K., Gundy C.M., Haasbeek C.J., Slotman B.J., Senan S. Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer. J Thorac Oncol 2012, 7:1148-1154.
53. Blomgren H., Lax I., Näslund I., Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870.
54. Uematsu M., Shioda A., Tahara K., Fukui T., Yamamoto F., Tsumatori G., et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998, 82:1062-1070.